Table 1.
Sensitivity and specificity of PCa-specific biomarkers for predicting any and high-grade PCa in empirical and simulated records of men with PSA level between 4.0 and 10.0 ng/mL*
| Source | Biomarker | Threshold | Any PCa |
High-grade PCa |
||
|---|---|---|---|---|---|---|
| Sensitivity, % (95% CI) | Specificity, % (95% CI) | Sensitivity, % (95% CI) | Specificity, % (95% CI) | |||
| Empirical | T2:ERG | 5 | 65.5 (61.2 to 69.6) | 58.4 (54.4 to 62.3) | 66.1 (60.3 to 72.0) | 51.5 (47.8 to 54.9) |
| PCA3 | 35 | 55.6 (51.3 to 59.6) | 76.0 (72.6 to 79.5) | 63.4 (57.2 to 69.3) | 68.9 (66.0 to 71.9) | |
| MiPS | 30% | 86.9 (84.0 to 89.9) | 45.6 (41.4 to 49.4) | 91.8 (87.9 to 95.3) | 37.3 (34.2 to 40.7) | |
| MiPShg | 10% | 92.0 (89.5 to 94.3) | 25.9 (22.2 to 29.2) | 95.3 (92.6 to 97.7) | 21.4 (18.6 to 24.2) | |
| Model | T2:ERG | 5 | 66.2 (65.0 to 67.4) | 58.1 (57.3 to 59.0) | 65.2 (62.9 to 67.3) | 51.6 (50.8 to 52.4) |
| PCA3 | 35 | 59.7 (58.5 to 61.0) | 69.5 (68.7 to 70.4) | 66.2 (64.0 to 68.4) | 62.6 (61.9 to 63.4) | |
| MiPS | 30% | 90.8 (90.0 to 91.5) | 38.6 (37.8 to 39.5) | 93.2 (92.1 to 94.3) | 31.2 (30.5 to 31.9) | |
| MiPShg | 10% | 94.5 (93.9 to 95.0) | 22.4 (21.6 to 23.1) | 96.5 (95.6 to 97.3) | 18.2 (17.6 to 18.8) | |
*
CI = confidence interval; T2:ERG = TMPRSS2:ERG gene fusion; PCA3 = prostate cancer antigen 3; MiPS = Michigan Prostate Score for any PCa; MiPShg = Michigan Prostate Score for high-grade PCa; PCa = prostate cancer; PSA = prostate-specific antigen.